Cover Image
市場調查報告書

過敏性結膜炎 : 開發中產品分析

Allergic Conjunctivitis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 192452
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
過敏性結膜炎 : 開發中產品分析 Allergic Conjunctivitis - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 73 Pages
簡介

過敏性結膜炎是覆蓋眼皮背面及結膜組織的透明層,因花粉、皮屑、霉、及其他過敏原因物質造成腫脹或發炎而發病。症狀包含極癢,眼瞼浮腫,覆蓋結膜的透明細胞層的血管擴張,及眼分泌物粘稠。使用抗組織胺藥物或抗發炎藥療法治療。

本報告涵括全球過敏性結膜炎治療藥的開發中產品,提供目前開發平台狀況和最新趨勢,後期階段及中止的計劃的資訊,主要企業及他們開發中的產品檢討等。

簡介

  • 調查範圍

過敏性結膜炎 - 概要

過敏性結膜炎 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 企業開發中的產品

過敏性結膜炎 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

過敏性結膜炎的治療藥開發企業

藥物簡介

過敏性結膜炎 - 暫停中的計劃

過敏性結膜炎 - 開發中止的產品

過敏性結膜炎 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9288IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Pipeline Review, H1 2017, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 2, 10 and 1 respectively.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Allergic Conjunctivitis - Overview
    • Allergic Conjunctivitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Allergic Conjunctivitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Allergic Conjunctivitis - Companies Involved in Therapeutics Development
    • Accolade Pharmaceuticals LLC
    • Aldeyra Therapeutics Inc
    • AlleCures Inc
    • Allergan Plc
    • Clevexel Pharma SAS
    • Griffin Discoveries BV
    • NicOx SA
    • Ocular Therapeutix Inc
    • Ohr Pharmaceutical Inc
    • Portola Pharmaceuticals Inc
    • Re-Pharm Ltd
    • Realm Therapeutics Plc
    • Sylentis SAU
    • Xencor Inc
  • Allergic Conjunctivitis - Drug Profiles
    • ADX-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AGN-229666 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Allergic Conjunctivitis and Allergic Rhinitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cetirizine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPC-888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CVXL-0074 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Allergic Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GD-134 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GD-136 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PR-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRT-2761 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-0217 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-266 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYL-116011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XmAb-7195 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Zafi-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zafirlukast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Allergic Conjunctivitis - Dormant Projects
  • Allergic Conjunctivitis - Discontinued Products
  • Allergic Conjunctivitis - Product Development Milestones
    • Featured News & Press Releases
      • Apr 18, 2017: Aldeyra Therapeutics Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial
      • Apr 11, 2017: Nicox announces PDUFA date for ZERVIATE NDA
      • Mar 09, 2017: Nicox resubmits AC-170 (ZERVIATE) NDA to the US FDA
      • Feb 07, 2017: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial
      • Jan 05, 2017: Realm Therapeutics to provide update on PR013 at the 2017 Dermatology Summit and Biotech Showcase
      • Dec 05, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 for the Treatment of Allergic Conjunctivitis
      • Nov 16, 2016: PuriCore provides update on key development program PR013
      • Nov 09, 2016: Nicox Provides Update on Latanoprostene bunod and AC-170
      • Nov 07, 2016: Aldeyra Therapeutics Announces Presentation of Phase 2 Allergic Conjunctivitis Results at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting
      • Oct 10, 2016: Nicox Receives Complete Response Letter from the FDA Related to GMP on NDA for AC-170
      • Sep 26, 2016: Aldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day
      • Jun 21, 2016: U.S. FDA grants Priority Review for Nicox AC-170 New Drug Application
      • Jun 06, 2016: Ocular Therapeutix Announces Topline Results of Second Phase 3 Clinical Trial of DEXTENZA for the Treatment of Allergic Conjunctivitis
      • Apr 19, 2016: Nicox submits New Drug Application for AC-170 to U.S. FDA
      • Feb 29, 2016: Aldeyra Therapeutics Reports Positive Results From Phase IIa Clinical Trial in Subjects With Allergic Conjunctivitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Allergic Conjunctivitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Allergic Conjunctivitis - Pipeline by Accolade Pharmaceuticals LLC, H1 2017
  • Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, H1 2017
  • Allergic Conjunctivitis - Pipeline by AlleCures Inc, H1 2017
  • Allergic Conjunctivitis - Pipeline by Allergan Plc, H1 2017
  • Allergic Conjunctivitis - Pipeline by Clevexel Pharma SAS, H1 2017
  • Allergic Conjunctivitis - Pipeline by Griffin Discoveries BV, H1 2017
  • Allergic Conjunctivitis - Pipeline by NicOx SA, H1 2017
  • Allergic Conjunctivitis - Pipeline by Ocular Therapeutix Inc, H1 2017
  • Allergic Conjunctivitis - Pipeline by Ohr Pharmaceutical Inc, H1 2017
  • Allergic Conjunctivitis - Pipeline by Portola Pharmaceuticals Inc, H1 2017
  • Allergic Conjunctivitis - Pipeline by Re-Pharm Ltd, H1 2017
  • Allergic Conjunctivitis - Pipeline by Realm Therapeutics Plc, H1 2017
  • Allergic Conjunctivitis - Pipeline by Sylentis SAU, H1 2017
  • Allergic Conjunctivitis - Pipeline by Xencor Inc, H1 2017
  • Allergic Conjunctivitis - Dormant Projects, H1 2017
  • Allergic Conjunctivitis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Allergic Conjunctivitis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Allergic Conjunctivitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top